Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol
- PMID: 33757953
- PMCID: PMC7993162
- DOI: 10.1136/bmjopen-2020-044996
Prospective observational cohort study of factors influencing trial participation in people with motor neuron disease (FIT-participation-MND): a protocol
Abstract
Introduction: Motor neuron disease (MND) is a rapidly progressive and fatal neurodegenerative disorder with limited treatment options. The Motor Neuron Disease Systematic Multi-Arm Randomised Adaptive Trial (MND-SMART) is a multisite UK trial seeking to address the paucity in effective disease-modifying drugs for people with MND (pwMND). Historically, neurological trials have been plagued by suboptimal recruitment and high rates of attrition. Failure to recruit and/or retain participants can cause insufficiently representative samples, terminated trials or invalid conclusions. This study investigates patient-specific factors affecting recruitment and retention of pwMND to MND-SMART. Improved understanding of these factors may improve trial protocol design, optimise recruitment and retention.
Methods and analysis: PwMND on the Scottish MND Register, Clinical Audit Research and Evaluation of MND (CARE-MND), will be invited to participate in a prospective observational cohort study that investigates factors affecting trial participation and attrition. We hypothesise that patient-specific factors will significantly affect trial recruitment and retention. Participants will complete the Hospital Anxiety and Depression Scale, 9-Item Patient Health Questionnaire and State-Trait Anxiety Inventory-Form Y to evaluate neuropsychiatric symptoms, the ALS-Specific Quality of Life Questionnaire-Brief Form and Centre for Disease Control and Prevention-Health-Related Quality of Life for quality of life and a novel study-specific questionnaire on Attitudes towards Clinical Trial Participation (ACT-Q). Clinical data on phenotype, cognition (Edinburgh Cognitive and Behavioural ALS Screen) and physical functioning (Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised) will also be collated. Caregivers will complete the Brief Dimensional Apathy Scale. After 12 months, a data request to MND-SMART will evaluate recruitment and retention. Descriptive statistics will summarise and compare assessments and participants reaching impairment thresholds. Variable groupings: attitudes, quality of life, cognition, behaviour, physical functioning, neuropsychiatric and phenotype. Univariate and multivariable logistic regression will explore association with participation/withdrawal in MND-SMART; presented as ORs and 95% CIs.
Ethics and dissemination: Ethical approval was provided by the West of Scotland Research Ethics Committee 3 (20/WS/0067) on 12 May 2020. The results of this study will be published in a peer-reviewed journal, presented at academic conferences and disseminated to participants and the public.
Keywords: clinical trials; motor neurone disease; neurology.
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: Professor Carson is a paid editor at Journal of Neurology, Neurosurgery and Psychiatry, and gives independent testimony in Court on a range of neuropsychiatric topics.
Similar articles
-
Factors impacting trial participation in people with motor neuron disease.J Neurol. 2024 Jan;271(1):543-552. doi: 10.1007/s00415-023-12010-8. Epub 2023 Oct 3. J Neurol. 2024. PMID: 37787812 Free PMC article.
-
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.BMJ Open. 2022 Jul 7;12(7):e064173. doi: 10.1136/bmjopen-2022-064173. BMJ Open. 2022. PMID: 35798516 Free PMC article. Clinical Trial.
-
Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.Cochrane Database Syst Rev. 2019 Dec 19;12(12):CD011742. doi: 10.1002/14651858.CD011742.pub3. Cochrane Database Syst Rev. 2019. PMID: 31853962 Free PMC article.
-
Relationship between neuropsychiatric disorders and cognitive and behavioural change in MND.J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):245-253. doi: 10.1136/jnnp-2019-321737. Epub 2019 Dec 23. J Neurol Neurosurg Psychiatry. 2020. PMID: 31871139
-
A systematic review of neuropsychiatric and cognitive assessments used in clinical trials for amyotrophic lateral sclerosis.J Neurol. 2021 Dec;268(12):4510-4521. doi: 10.1007/s00415-020-10203-z. Epub 2020 Sep 10. J Neurol. 2021. PMID: 32910255 Free PMC article.
Cited by
-
Asynchronous online focus groups for research with people living with amyotrophic lateral sclerosis and family caregivers: usefulness, acceptability and lessons learned.BMC Med Res Methodol. 2023 Oct 6;23(1):222. doi: 10.1186/s12874-023-02051-y. BMC Med Res Methodol. 2023. PMID: 37803257 Free PMC article.
-
Factors impacting trial participation in people with motor neuron disease.J Neurol. 2024 Jan;271(1):543-552. doi: 10.1007/s00415-023-12010-8. Epub 2023 Oct 3. J Neurol. 2024. PMID: 37787812 Free PMC article.
-
Towards a multi-arm multi-stage platform trial of disease modifying approaches in Parkinson's disease.Brain. 2023 Jul 3;146(7):2717-2722. doi: 10.1093/brain/awad063. Brain. 2023. PMID: 36856727 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous